Targeting telomerase: Therapeutic options for cancer treatment

Telomeres and Telomerase in Ageing, Disease, and Cancer: Molecular Mechanisms of Adult Stem Cell Ageing

Volumn , Issue , 2008, Pages 247-283

  Keith, W Nicol ^a   Bilsland, Alan E ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39449115877     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-73709-4_13     Document Type: Chapter

References (244)

1. Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, De Groot N, Hochberg A (2000) Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2:539-44
2. Adotevi O, Mollier K, Neuveut C, Cardinaud S, Boulanger E, Mignen B, Fridman WH, Zanetti M, Charneau P, Tartour E, Lemonnier F, Langlade-Demoyen P (2006) Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 12:3158-67
3. Akalin A, Elmore LW, Forsythe HL, Amaker BA, McCollum ED, Nelson PS, Ware JL, Holt SE (2001) A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res 61:4791-96
4. Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC (2003a) Effects of oligonucleotide N3'?P5' thiophosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 63:6187-94
5. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC (2003b) Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 63:18-21
6. Aldous WK, Marean AJ, De Hart MJ, Matej LA, Moore KH (1999) Effects of tamoxifen on telomerase activity in breast carcinoma cell lines. Cancer 85:1523-29
7. Amarnath SM, Dyer CE, Ramesh A, Iwuagwu O, Drew PJ, Greenman J (2004) In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int J Oncol 25:211-17
8. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S (2001) Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97:2903-07
9. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, Chin AC, Harley CB, Gryaznov S (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63:3931-39
10. Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P, Levy F, Speiser DE, Valmori D (2001) Lack of tumor recognition by hTERT peptide 540-548-specific CD8 (+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31:2642-51
11. Bajpai AK, Park JH, Moon IJ, Kang H, Lee YH, Doh KO, Suh SI, Chang BC, Park JG (2005) Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTERC. Oncogene 24:6492-6501
12. Beltz L, Moran R, Elsawy O, Sadler J, Jurgenson J (1999) The effects of telomerase inhibitors on lymphocyte function. Anticancer Res 19:3205-11
13. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515-25
14. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with highgrade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66:1234-40
15. Bilsland AE, Fletcher-Monaghan A and Keith WN (2005) Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia 7:1020-29
16. Bilsland AE, Merron A, Vassaux G, Keith WN (2007) Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res 67:1299-1307
17. Bilsland AE, Stevenson K, Atkinson S, Kolch W, Keith WN (2006) Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3. Cancer Res 66:1363-70
18. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Jeffry Evans TR, Ganly I, Knox RJ, Plumb JA, Nicol Keith W (2003) Selective ablation of human cancer cells by telomerasespecific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22:370-80
19. Binz N, Shalaby T, Rivera P, Shin-ya K, Grotzer MA (2005) Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer 41:2873-81
20. Bortolanza S, Qian C, Kramer MG, Gomar C, Prieto J, Farinati F, Hernandez-Alcoceba R (2005) An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells. J Mol Med 83:736-47
21. Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, Owens J, Vaidyanathan G, Carruthers R, Dorrens J, Zalutsky MR (2004) An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiationmediated bystander effects. J Gene Med 6:937-47
22. Brown T, Sigurdson E, Rogatko A, Broccoli D (2003) Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol 10:910-15
23. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Moller M, Eriksen JA, Gaudernack G (2006) Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55:1553-64
24. Budiyanto A, Bito T, Kunisada M, Ashida M, Ichihashi M, Ueda M (2003) Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. J Invest Dermatol 121:1088-94
25. Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ, Double JA, Neidle S (2005) The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 65:1489-96
26. Canales BK, Li Y, Thompson MG, Gleason JM, Chen Z, Malaeb B, Corey DR, Herbert BS, Shay JW, Koeneman KS (2006) Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. Urol Oncol 24:141-51
27. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM (2006) Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7:R100
28. Carpenter EL, Vonderheide RH (2006) Telomerase-based immunotherapy of cancer. Expert Opin Biol Ther 6:1031-39
29. Chamuleau ME, Ossenkoppele GJ, Van De Loosdrecht AA (2006) MHC class II molecules in tumor immunology: prognostic marker and target for immune modulation. Immunobiology 211:619-25
30. Chang JT, Lu YC, Chen YJ, Tseng CP, Chen YL, Fang CW, Cheng AJ (2006) hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. Br J Cancer 94:870-78
31. Chang JY, Zhang X, Komaki R, Cheung R, Fang B (2006) Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 64:1482-94
32. Chang W, Dynek JN, Smith S (2003) TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes Dev 17:1328-33
33. Chen Z, Monia BP, Corey DR (2002) Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2'-O-methoxyethyl oligonucleotides. J Med Chem 45:5423-25
34. Chen Z, Koeneman KS, Corey DR (2003) Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 63:5917-25
35. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y (2001) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10:53-58
36. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9:3312-19
37. D'Adda Di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426:194-98
38. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, Lauritsch I, Muller E, Pascolo E, Sauter G, Pantic M, Martens UM, Wenz C, Lingner J, Kraut N, Rettig WJ, Schnapp A (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. Embo J 20:6958-68
39. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C (2006) Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108:1021-29
40. De Chastonay J (2005) The outlook for peptide drugs and the intricate relationship between the Active Pharmaceutical Ingredients manufacturer and their sponsors. J Pept Sci 11:754-5
41. De Laporte L, Cruz Rea J, Shea LD (2006) Design of modular non-viral gene therapy vectors. Biomaterials 27:947-54
42. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE, Shay JW (2005) In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 65:7866-73
43. Di Masi JA, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25:209-16
44. Di Masi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151-85
45. Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL (2005) Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42:1127-36
46. Downey MG, Going JJ, Stuart RC, Keith WN (2001) Expression of telomerase RNA in oesophageal and oral cancer. J Oral Pathol Med 30:577-81
47. Dufes C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schatzlein AG (2005) Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 65:8079-84
48. Duncan VE, Ajmani PS, Hughes JA (1998) Cellular delivery is a major obstacle for oligodeoxynucleotide inhibition of telomerase activity. Anticancer Res 18:4105-08
49. Eggert US, Mitchison TJ (2006) Small molecule screening by imaging. Curr Opin Chem Biol 10:232-37
50. Elayadi AN, Demieville A, Wancewicz EV, Monia BP, Corey DR (2001) Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res 29:1683-89
51. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM (2005) Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105:1742-49
52. Emens LA (2006) Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol 25:415-43
53. Evans TR, Keith WN (2004) Intra-peritoneal administration of genetic therapies: promises and pitfalls. Minerva Ginecol 56:529-38
54. Everts B, Van Der Poel HG (2005) Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12:141-61
55. Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S, Ferrera F, Romagnoli A, Basso M, Contini P, Rizzi M, Ghio M, Benatti U, Damonte G, Ravetti JL, Carmignani G, Zanetti M, Indiveri F (2006) Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood 107:1505-12
56. Folini M, De Marco C, Orlandi L, Daidone MG, Zaffaroni N (2000a) Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur J Cancer 36:2137-45
57. Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N (2000b) Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J Invest Dermatol 114:259-67
58. Folini M, Berg K, Millo E, Villa R, Prasmickaite L, Daidone MG, Benatti U, Zaffaroni N (2003) Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Res 63:3490-94
59. Forsythe HL, Jarvis JL, Turner JW, Elmore LW, Holt SE (2001) Stable association of hsp90 and p23, but Not hsp70, with active human telomerase. J Biol Chem 276:15571-74
60. Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M (2006) High-throughput screening: update on practices and success. J Biomol Screen 11:864-69
61. Fratantoni JC, Dzekunov S, Singh V, Liu LN (2003) A non-viral gene delivery system designed for clinical use. Cytotherapy 5:208-10
62. Frisch SM, Mymryk JS (2002) Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 3:441-52
63. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK, Jablons DM (2007) An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 67:573-79
64. Gan Y, Mo Y, Johnston J, Lu J, Wientjes MG, Au JL (2002) Telomere maintenance in telomerasepositive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Lett 527:10-14
65. Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S (2005) Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 174:8210-18
66. Glasgow JN, Everts M, Curiel DT (2006) Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 13:830-44
67. Glukhov AI, Zimnik OV, Gordeev SA, Severin SE (1998) Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem Biophys Res Commun 248:368-71
68. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-87
69. Goldkorn A, Blackburn EH (2006) Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res 66:5763-71
70. Gomez D, Paterski R, Lemarteleur T, Shin-Ya K, Mergny JL, Riou JF (2004) Interaction of telomestatin with the telomeric single-strand overhang. J Biol Chem 279:41487-94
71. Gomez D, Wenner T, Brassart B, Douarre C, O'Donohue MF, El Khoury V, Shin-Ya K, Morjani H, Trentesaux C, Riou JF (2006) Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. J Biol Chem 281:38721-29
72. Gowan SM, Heald R, Stevens MF, Kelland LR (2001) Potent inhibition of telomerase by smallmolecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol 60:981-88
73. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR (2002) A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 61:1154-62
74. Grace MJ, Xie L, Musco ML, Cui S, Gurnani M, Di Giacomo R, Chang A, Indelicato S, Syed J, Johnson R, Nielsen LL (1999) The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies. Am J Pathol 155:1869-78
75. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-93
76. Grill J, Lamfers ML, Van Beusechem VW, Dirven CM, Pherai DS, Kater M, Van Der Valk P, Vogels R, Vandertop WP, Pinedo HM, Curiel DT, Gerritsen WR (2002) The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 6:609-14
77. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G (2004) Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 64:4906-11
78. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425-33
79. Gryaznov S, Pongracz K, Matray T, Schultz R, Pruzan R, Aimi J, Chin A, Harley C, Shea-Herbert B, Shay J, Oshima Y, Asai A, Yamashita Y (2001) Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 20:401-10
80. Gryaznov S, Asai A, Oshima Y, Yamamoto Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, Chin A, Harley C, Akinaga S, Yamashita Y (2003) Oligonucleotide N3' ? P5' thiophosphoramidate telomerase template antagonists as potential anticancer agents. Nucleosides Nucleotides Nucleic Acids 22:577-81
81. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B (2000) Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60:5359-64
82. Hamilton SE, Simmons CG, Kathiriya IS, Corey DR (1999) Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem Biol 6:343-51
83. Hamilton SE, Pitts AE, Katipally RR, Jia X, Rutter JP, Davies BA, Shay JW, Wright WE, Corey DR (1997) Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry 36:11873-80
84. Hao ZM, Luo JY, Cheng J, Li L, He D, Wang QY and Yang GX (2005) Intensive inhibition of hTERT expression by a ribozyme induces rapid apoptosis of cancer cells through a telomere length-independent pathway. Cancer Biol Ther 4:1098-1103
85. Herbert BS, Pongracz K, Shay JW, Gryaznov SM (2002) Oligonucleotide N3'?P5' phosphoramidates as efficient telomerase inhibitors. Oncogene 21:638-42
86. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM (2005) Lipid modification of GRN163, an N3'?P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24:5262-68
87. Hermiston TW, Kirn DH (2005) Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development. Mol Ther 11:496-507
88. Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99:12275-80
89. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF (2002) New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 13:1737-50
90. Hinz T, Buchholz CJ, Van Der Stappen T, Cichutek K, Kalinke U (2006) Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother 29:472-76
91. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansen S, Kojima S, Nadler LM (2006) Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 108:2662-68
92. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS (2006) Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 12:3184-92
93. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Ouellette M, Trager JB, Morin GB, Toft DO, Shay JW, Wright WE, White MA (1999) Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 13:817-26
94. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G (2007) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1-15
95. Horikawa I, Barrett JC (2003) Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24:1167-76
96. Huang Q, Zhang X, Wang H, Yan B, Kirkpatrick J, Dewhrist MW, Li CY (2004) A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 10:1439-45
97. Huang SL, Wu Y, Yu H, Zhang P, Zhang XQ, Ying L, Zhao HF (2006) Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacol Sin 27:242-48
98. Huang TG, Savontaus MJ, Shinozaki K, Sauter B V, Woo SL (2003) Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 10:1241-47
99. Humphreys RE, Hillman GG, Von Hofe E, Xu M (2004) Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy. Cell Mol Immunol 1:180-85
100. Incles CM, Schultes CM, Kelland LR, Neidle S (2003) Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. Mol Pharmacol 64:1101-08
101. Incles CM, Schultes CM, Kempski H, Koehler H, Kelland LR, Neidle S (2004) A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. Mol Cancer Ther 3:1201-06
102. Inui T, Shinomiya N, Fukasawa M, Kobayashi M, Kuranaga N, Ohkura S, Seki S (2002) Growthrelated signaling regulates activation of telomerase in regenerating hepatocytes. Exp Cell Res 273:147-56
103. Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS (2004) Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 11:174-85
104. Ito H, Kanzawa T, Miyoshi T, Hirohata S, Kyo S, Iwamaru A, Aoki H, Kondo Y, Kondo S (2005) Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther 16:685-98
105. Ji XM, Xie CH, Fang MH, Zhou FX, Zhang WJ, Zhang MS, Zhou YF (2006) Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy. Acta Pharmacol Sin 27:1185-91
106. Kanazawa Y, Ohkawa K, Ueda K, Mita E, Takehara T, Sasaki Y, Kasahara A, Hayashi N (1996) Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 225:570-76
107. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA (2003) A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4:463-76
108. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285-92
109. Kazhdan I, Long L, Montellano R, Cavazos DA, Marciniak RA (2006) Targeted gene therapy for breast cancer with truncated Bid. Cancer Gene Ther 13:141-49
110. Keith WN, Sarvesvaran J, Downey M (2002) Analysis of telomerase RNA gene expression by in situ hybridization. Methods Mol Biol 191:65-81
111. Keith WN, Bilsland A, Evans TR, Glasspool RM (2002) Telomerase-directed molecular therapeutics. Expert Rev Mol Med 2002:1-25
112. Keith WN, Bilsland A, Hardie M, Evans TR (2004) Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol 1:88-96
113. Kelland LR (2005) Overcoming the immortality of tumor cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur J Cancer 41:971-79
114. Kelland LR, Green C, Clark S, Griffiths-Johnson D, Dunmore K, Robson M, Martins C, Gunaratnam M, Reszka T, Neidle S (2005) A small molecule trisubstituted acridine-based telomere targeting agent (TTAs) possessing preclinical in vivo antitumor activity. In: Proceedings of the American Association for Cancer Research, Volume 46, 2005. Abstract no. 2837
115. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J, Sohn JH, Kim H, Yun CO (2003a) Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14:1415-28
116. Kim MY, Gleason-Guzman M, Izbicka E, Nishioka D, Hurley LH (2003b) The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res 63:3247-56
117. Kiss-Toth E, Guesdon FM, Wyllie DH, Qwarnstrom EE, Dower SK (2000) A novel mammalian expression screen exploiting green fluorescent protein-based transcription detection in single cells. J Immunol Methods 239:125-35
118. Kiss-Toth E, Wyllie DH, Holland K, Marsden L, Jozsa V, Oxley KM, Polgar T, Qwarnstrom EE, Dower SK (2006) Functional mapping and identification of novel regulators for the Toll/Interleukin-1 signalling network by transcription expression cloning. Cell Signal 18:202-14
119. Koga S, Kondo Y, Komata T, Kondo S (2001) Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther 8:654-58
120. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S (2000) A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 11:1397-1406
121. Kohno M, Pouyssegur J (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-11
122. Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S (2000) Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther 7:2071-79
123. Komata T, Koga S, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S, Kondo Y (2001a) A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol 19:1015-20
124. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S, Kondo S (2001b) Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61:5796-5802
125. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK (1998) Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16:3323-30
126. Kondo Y, Koga S, Komata T, Kondo S (2000) Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 19:2205-11
127. Kosciolek BA, Kalantidis K, Tabler M, Rowley PT (2003) Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2:209-16
128. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, Meye A (2003) Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 9:3794-3800
129. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ (2006) Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 62:15-26
130. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH (2007) Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 7:131-39
131. Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, Kennedy AW, Silverman RH, Cowell JK (2000) 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 76:183-92
132. Lanson NA, Jr., Friedlander PL, Schwarzenberger P, Kolls JK, Wang G (2003) Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 63:7936-41
133. Lanzilli G, Fuggetta MP, Tricarico M, Cottarelli A, Serafino A, Falchetti R, Ravagnan G, Turriziani M, Adamo R, Franzese O, Bonmassar E (2006) Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol 28:641-48
134. Lavelle F, Riou JF, Laoui A, Mailliet P (2000) Telomerase: a therapeutic target for the third millennium? Crit Rev Oncol Hematol 34:111-26
135. Lee SH, Kim JW, Lee HW, Cho YS, Oh SH, Kim YJ, Jung CH, Zhang W, Lee JH (2003) Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression. Oncogene 22:381-91
136. Leonetti C, Amodei S, D'Angelo C, Rizzo A, Benassi B, Antonelli A, Elli R, Stevens MF, D'Incalci M, Zupi G, Biroccio A (2004) Biological activity of the G-quadruplex ligand RHPS4 (3, 11-difluoro-6, 8, 13-trimethyl-8H-quino[4, 3, 2-kl]acridinium methosulfate) is associated with telomere capping alteration. Mol Pharmacol 66:1138-46
137. Lesko LJ (2007) Paving the critical path: how can clinical pharmacology help achieve the vision? Clin Pharmacol Ther 81:170-77
138. Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR, Reiter Y (2002) Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 62:3184-94
139. Li B, Fan J, Liu X, Qi R, Bo L, Gu J, Qian C (2006) Suppression of colorectal tumor growth by regulated survivin targeting. J Mol Med 84:1077-86
140. Li S, Crothers J, Haqq CM, Blackburn EH (2005) Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 280:23709-17
141. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE (2007) Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 18:161-70
142. Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA, Fang B (2002) Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 62:3620-25
143. Lin T, Zhang L, Davis J, Gu J, Nishizaki M, Ji L, Roth JA, Xiong M, Fang B (2003) Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 8:441-48
144. Liu J, Zou WG, Lang MF, Luo J, Sun LY, Wang XN, Qian QJ, Liu XY (2002) Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int J Oncol 21:661-66
145. Liu TC, Kirn D (2007) Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 67:429-32
146. Liu TC, Galanis E, Kirn D (2007) Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4:101-17
147. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, Von Zglinicki T (2001) Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61:3053-61
148. Maecker B, Von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Anderson KC, Nadler LM, Schultze JL (2005) Rare naturally occurring immune responses to three epitopes from the widely expressed tumor antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol 141:558-62
149. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP (2001) The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8:568-78
150. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, De Caprio JA, Weinberg RA, Stewart SA, Hahn WC (2003) Telomerase maintains telomere structure in normal human cells. Cell 114:241-53
151. Matthes E, Lehmann C (1999) Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res 27:1152-58
152. Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT (2001) Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 113:779-84
153. Melana SM, Holland JF, Pogo BG (1998) Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'- deoxythymidine. Clin Cancer Res 4:693-96
154. Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6:409-14
155. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97:4796-4801
156. Mitchison TJ (2005) Small-molecule screening and profiling by using automated microscopy. Chembiochem 6:33-39
157. Miyoshi T, Hirohata S, Ogawa H, Doi M, Obika M, Yonezawa T, Sado Y, Kusachi S, Kyo S, Kondo S, Shiratori Y, Hudson BG, Ninomiya Y (2006) Tumor-specific expression of the RGD-alpha3 (IV) NC1 domain suppresses endothelial tube formation and tumor growth in mice. Faseb J 20:1904-06
158. Mukai S, Kondo Y, Koga S, Komata T, Barna BP, Kondo S (2000) 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 60:4461-67
159. Murakami J, Nagai N, Shigemasa K, Ohama K (1999) Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 35:1027-34
160. Naasani I, Seimiya H, Tsuruo T (1998) Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 249:391-96
161. Naasani I, Seimiya H, Yamori T, Tsuruo T (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59:4004-11
162. Naasani I, Oh-Hashi F, Oh-Hara T, Feng WY, Johnston J, Chan K, Tsuruo T (2003) Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 63:824-30
163. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964-71
164. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011-17
165. Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K, Ohyashiki JH, Ohyashiki K (2003) Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 17:560-67
166. Nakamura M, Masutomi K, Kyo S, Hashimoto M, Maida Y, Kanaya T, Tanaka M, Hahn WC, Inoue M (2005) Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 16:859-68
167. Nakamura M, Kyo S, Kanaya T, Yatabe N, Maida Y, Tanaka M, Ishida Y, Fujii C, Kondo T, Inoue M, Mukaida N (2004) hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin. Cancer Gene Ther 11:1-7
168. Neidle S, Harrison RJ, Reszka AP, Read MA (2000) Structure-activity relationships among guanine-quadruplex telomerase inhibitors. Pharmacol Ther 85:133-09
169. Nicol Keith W, Jeffry Evans TR, Glasspool RM (2001) Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 195:404-14
170. Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR (1996) Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol 14:615-19
171. Nosrati M, Li S, Bagheri S, Ginzinger D, Blackburn EH, Debs RJ, Kashani-Sabet M (2004) Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin Cancer Res 10:4983-90
172. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C (2006) A phase I trial of twice-weekly 17-allylamino-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 12:6087-93
173. Ozawa T, Gryaznov SM, Hu LJ, Pongracz K, Santos RA, Bollen AW, Lamborn KR, Deen DF (2004) Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-oncol 6:218-26
174. Pallini R, Sorrentino A, Pierconti F, Maggiano N, Faggi R, Montano N, Maira G, Larocca LM, Levi A, Falchetti ML (2006) Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int J Cancer 118:2158-67
175. Park K, Yi SY, Lee CS, Kim KE, Pai HS, Seol DW, Chung BH, Kim M (2007) A split enhanced green fluorescent protein-based reporter in yeast two-hybrid system. Protein J 26:107-16
176. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA (2004) Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10:4688-98
177. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A (2002) Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277:15566-72
178. Paulmurugan R, Gambhir SS (2003) Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation. Anal Chem 75:1584-89
179. Pendino F, Flexor M, Delhommeau F, Buet D, Lanotte M, Segal-Bendirdjian E (2001) Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci USA 98:6662-67
180. Pitts AE, Corey DR (1998) Inhibition of human telomerase by 2'-O-methyl-RNA. Proc Natl Acad Sci USA 95:11549-54
181. Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ, Evans TR, Keith WN (2001) Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20:7797-7803
182. Rajwa B, McNally HA, Varadharajan P, Sturgis J, Robinson JP (2004) AFM/CLSM data visualization and comparison using an open-source toolkit. Microsc Res Tech 64:176-84
183. Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, Reddy PS, Yu DC (2006) CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 12:305-13
184. Read M, Harrison RJ, Romagnoli B, Tanious FA, Gowan SH, Reszka AP, Wilson WD, Kelland LR, Neidle S (2001) Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc Natl Acad Sci USA 98:4844-49
185. Rha SY, Izbicka E, Lawrence R, Davidson K, Sun D, Moyer MP, Roodman GD, Hurley L, Von Hoff D (2000) Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin Cancer Res 6:987-93
186. Rock KL, Goldberg AL (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739-79
187. Sams-Dodd F (2005) Target-based drug discovery: is something wrong? Drug Discov Today 10:139-47
188. Saretzki G, Ludwig A, Von Zglinicki T, Runnebaum IB (2001) Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther 8:827-34
189. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN (1999) Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 20:1649-51
190. Sawada T, Yamada O, Yoshimura N, Hatori K, Fuchinoue S, Teraoka S (2002) Xenoantigen, an alphaGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line. Cancer Cell Int 2:14
191. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-06
192. Schreurs MW, Kueter EW, Scholten KB, Kramer D, Meijer CJ, Hooijberg E (2005) Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol Immunother 54:703-12
193. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62:2600-05
194. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743-55
195. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T (2005) Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 7:25-37
196. Seimiya H, Sawada H, Muramatsu Y, Shimizu M, Ohko K, Yamane K, Tsuruo T (2000) Involvement of 14-3-3 proteins in nuclear localization of telomerase. Embo J 19:2652-61
197. Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, Tsuruo T (2002) Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 1:657-65
198. Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC (2004) Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 10:770-76
199. Shammas MA, Koley H, Batchu RB, Bertheau RC, Protopopov A, Munshi NC, Goyal RK (2005) Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer 4:24
200. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787-91
201. Shay JW, Wright WE (2006) Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 5:577-84
202. Shieh GS, Shiau AL, Yo YT, Lin PR, Chang CC, Tzai TS, Wu CL (2006) Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 66:9957-66
203. Smith S, Giriat I, Schmitt A, De Lange T (1998) Tankyrase, a poly (ADP-ribose) polymerase at human telomeres. Science 282:1484-87
204. Soder AI, Going JJ, Kaye SB, Keith WN (1998) Tumor specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene 16:979-83
205. Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN (1997) Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 14:1013-21
206. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J (2002) Enhanced induction of telomerase-specific CD4 (+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 62:5041-48
207. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J (2005) Telomerase mRNA-transfected dendritic cells stimulate antigenspecific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174:3798-3807
208. Suenaga M, Yamaguchi A, Soda H, Orihara K, Tokito Y, Sakaki Y, Umehara M, Terashi K, Kawamata N, Oka M, Kohno S, Tei C (2006) Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res 26:3387-91
209. Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO, Jenkins TC, Neidle S, Hurley LH (1997) Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem 40:2113-16
210. Tahara H, Shin-Ya K, Seimiya H, Yamada H, Tsuruo T, Ide T (2006) G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene 25:1955-66
211. Tajima K, Ito Y, Demachi A, Nishida K, Akatsuka Y, Tsujimura K, Hida T, Morishima Y, Kuwano H, Mitsudomi T, Takahashi T, Kuzushima K (2004) Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. Int J Cancer 110:403-12
212. Takai H, Smogorzewska A, De Lange T (2003) DNA damage foci at dysfunctional telomeres. Curr Biol 13:1549-56
213. Takeuchi H, Kanzawa T, Kondo Y, Komata T, Hirohata S, Kyo S, Kondo S (2004) Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells. Int J Oncol 25:57-63
214. Tauchi T, Shin-ya K, Sashida G, Sumi M, Okabe S, Ohyashiki JH, Ohyashiki K (2006) Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25:5719-25
215. Tressler R, Kornbrust D, Chin A, Harley C, Behrs M, Elias L (2006) GRN163L, a telomerase inhibitor under development for cancer treatment: data guiding clinical trial design. European Journal of Cancer Supplements 4:188
216. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-48
217. Villa R, Folini M, Lualdi S, Veronese S, Daidone MG, Zaffaroni N (2000) Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. FEBS Lett 473:241-48
218. Villa R, Folini M, Porta CD, Valentini A, Pennati M, Daidone MG, Zaffaroni N (2003) Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis 24:851-59
219. Vonderheide RH (2002) Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21:674-79
220. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-79
221. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM (2001) Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7:3343-78
222. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10:828-39
223. Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, Moore MA (2004a) Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103:258-66
224. Wang YG, Wang JH, Zhang YH, Gu Q, Liu XY (2004b) Antitumor effect of a novel adeno-associated virus vector targeting to telomerase activity in tumor cells. Acta Biochim Biophys Sin (Shanghai) 36:492-500
225. Ward RJ, Autexier C (2005) Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 68:779-86
226. White LK, Wright WE, Shay JW (2001) Telomerase inhibitors. Trends Biotechnol 19:114-20
227. Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, Kuhnel F (2003) A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63:3181-88
228. Wisman GB, De Jong S, Meersma GJ, Helder MN, Hollema H, De Vries EG, Keith WN, Van Der Zee AG (2000) Telomerase in (pre) neoplastic cervical disease. Hum Pathol 31:1304-12
229. Won J, Chang S, Oh S, Kim TK (2004) Small-molecule-based identification of dynamic assembly of E2F-pocket protein-histone deacetylase complex for telomerase regulation in human cells. Proc Natl Acad Sci USA 101:11328-33
230. Wong JM, Kusdra L, Collins K (2002) Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat Cell Biol 4:731-36
231. Wong SK (2004) A 384-well cell-based phospho-ERK assay for dopamine D2 and D3 receptors. Anal Biochem 333:265-72
232. Yatabe N, Kyo S, Kondo S, Kanaya T, Wang Z, Maida Y, Takakura M, Nakamura M, Tanaka M, Inoue M (2002) 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 9:624-30
233. Yeo M, Rha SY, Jeung HC, Hu SX, Yang SH, Kim YS, An SW, Chung HC (2005) Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int J Cancer 114:484-89
234. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, Niwa K, Tamaya T (1998) Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 58:5406-10
235. Yokoyama Y, Takahashi Y, Shinohara A, Wan X, Takahashi S, Niwa K, Tamaya T (2000) The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem Biophys Res Commun 273:316-21
236. Zahler AM, Williamson JR, Cech TR, Prescott DM (1991) Inhibition of telomerase by G-quartet DNA structures. Nature 350:718-20
237. Zhang PH, Zou L, Tu ZG (2006a) RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 131:143-49
238. Zhang Z, Yang X, Zhang Y, Zeng B, Wang S, Zhu T, Roden RB, Chen Y, Yang R (2006b) Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 12:4933-39
239. Zhao HF, Kiyota T, Chowdhury S, Purisima E, Banville D, Konishi Y, Shen SH (2004) A mammalian genetic system to screen for small molecules capable of disrupting protein-protein interactions. Anal Chem 76:2922-27
240. Zheng JN, Sun YF, Pei DS, Liu JJ, Chen JC, Li W, Sun XQ, Shi QD, Han RF, Ma TX (2006) Inhibition of proliferation and induction of apoptosis in human renal carcinoma cells by antitelomerase small interfering RNAs. Acta Biochim Biophys Sin (Shanghai) 38:500-06
241. Zhou JM, Zhu XF, Lu YJ, Deng R, Huang ZS, Mei YP, Wang Y, Huang WL, Liu ZC, Gu LQ, Zeng YX (2006) Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene 25:503-11
242. Zielinska D, Pongracz K, Gryaznov S (2005) A new approach to oligonucleotide N3'→P5' phosphoramidate building blocks. Nucleosides Nucleotides Nucleic Acids 24:1063-67
243. Zou L, Zhang P, Luo C, Tu Z (2006) shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol 57:328-34
244. Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C, Liu X (2004) A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23:457-64